Recently, Vice Chairman of the Guangdong Provincial Committee of the Chinese People's Political Consultative Conference and Secretary of the Foshan Municipal Party Committee Ke Zheng led a delegation of government officials on a visit to RainMed Medical to investigate the local development of the medical industry. Professor Yunlong Huo, one of the founding shareholders of RainMed Medical, Vice President and Secretary of the Board of RainMed Medical Kangjian Liu, and Vice President of RainMed Medical Yang Gu accompanied the delegation and gave detailed introductions on RainMed’s development, strategic planning, and innovative product systems. Secretary Zheng recognized the innovation of RainMed Medical's products and praised the company as a leading medical device enterprise that has played a significant role in the local economic and industrial development of Suzhou.

Zhiyong Liu, Deputy Secretary of the Foshan Municipal Party Committee and Secretary of the Shunde District Committee, Chengshu Ge, Member of the Standing Committee of the Foshan Municipal Party Committee and Secretary-General, Xifeng Ding, Member of the Standing Committee of the Foshan Municipal Party Committee and Minister of the United Front Work Department, Yongtai Yang, Secretary of the Gao Ming District Committee of Foshan City and Vice Chairman of the Municipal People's Congress Standing Committee, as well as relevant officials from various district committees and municipal departments participated in this visit.

RainMed Medical is a national high-tech enterprise with comprehensive hardware and software capabilities. Since its establishment, the company has differentiated its layout and implemented the strategic goal of vascular intervention surgery robots in steps. Currently, RainMed Medical has commercialized the caFFR system, the most accurate coronary functional detection product in China, and the caIMR system, the only non-invasive coronary microcirculation detection product in the world. The company continues to promote the research and commercialization of cutting-edge vascular disease diagnosis and treatment technologies such as the FlashBot vascular intervention surgery robot and the Flash IVL shock wave balloon, providing an integrated diagnosis and treatment solution for vascular operating rooms and creating a new era of precise medical intervention.